LABT Lakewood-amedex Biotherapeutics Inc.
Fundamentals / CIK 0002079272 / USDLakewood-amedex Biotherapeutics Inc. reported $3.60M in total assets through September 30, 2026 from SEC EDGAR filings.
Audited annual (10-K / 20-F) and quarterly (10-Q) statements parsed directly from SEC EDGAR CompanyFacts. Open LABT in the Convexity terminal for live prices, valuation multiples, transcripts, and insider flow.
-
Revenue FY 2026-- Sep 30, 2026
-
Operating Income FY 2026-- Operating profit
-
Net Income FY 2026-- GAAP bottom line
-
Diluted EPS FY 2026-- Split-adjusted
-
Free Cash Flow FY 2026-- Operating CF less CapEx
-
Cash & ST Investments Sep 30, 2026$3.32M Total debt: $71K
Financial statements and ratios
Reported in USD. Per-share figures and share counts are adjusted for stock splits from SEC filings.
Income Statement (Annual) · Reported in USD · Newest filing period first.
Income Statement (Quarterly) · Reported in USD · Newest filing period first.
| Income Statement | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|---|
| Cost of Revenue | -- | -- | $507K | -- | -- | -- |
| Research & Development | $733K | $503K | $182K | $753K | $147K | $170K |
| Total Operating Expenses | $1.51M | $3.79M | $887K | $1.88M | $637K | $543K |
| Operating Income | -$1.51M | -$3.79M | -$887K | -$1.88M | -$637K | -$543K |
| EBITDA | -$1.51M | -$3.79M | -$886K | -$1.88M | -$636K | -$541K |
| Interest Income | $36K | $28K | $1.1K | $11K | $5.4K | $4.3K |
| Interest Expense | $0 | $11K | $38K | $38K | $24K | $1.3K |
| Net Income | -$1.47M | -$3.77M | -$923K | -$1.91M | -$656K | -$540K |
| Basic EPS | -$0.62 | -$2.75 | -$0.20 | -$3.46 | -$1.66 | -$0.15 |
| Diluted EPS | -$0.62 | -$2.75 | -$0.20 | -$3.46 | -$1.66 | -$0.15 |
| Basic Shares Outstanding | 2.4M | 1.4M | 7.0M | 696.9K | 694.5K | 6.9M |
| Diluted Shares Outstanding | 2.4M | 1.4M | 7.0M | 696.9K | 694.5K | 6.9M |
Balance Sheet (Annual) · Reported in USD · Newest filing period first.
Balance Sheet (Quarterly) · Reported in USD · Newest filing period first.
| Balance Sheet | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
|---|---|---|---|---|
| Cash & Cash Equivalents | $2.82M | $2.58M | $12K | $236K |
| Short-Term Investments | $500K | $2.00M | -- | -- |
| Cash & Short-Term Investments | $3.32M | $4.58M | $12K | $236K |
| Total Current Assets | $3.51M | $4.85M | $51K | $305K |
| Property, Plant & Equipment, Net | $5.7K | $6.9K | $8.1K | $9.2K |
| Other Non-Current Assets | $7.8K | $7.8K | $8.1K | $8.1K |
| Total Non-Current Assets | $84K | $115K | $146K | $176K |
| Total Assets | $3.60M | $4.96M | $196K | $482K |
| Accounts Payable | $240K | $166K | $548K | $381K |
| Total Current Liabilities | $673K | $629K | $3.03M | $2.41M |
| Total Non-Current Liabilities | $0 | $0 | $10K | $41K |
| Total Liabilities | $673K | $629K | $3.04M | $2.45M |
| Total Debt (incl. Leases) | $71K | $102K | $131K | $160K |
| Common Stock | $366 | $217 | $704 | $70 |
| Retained Earnings | -$70.11M | -$68.64M | -$54.27M | -$53.35M |
| Total Stockholders' Equity | $2.93M | $4.33M | -$2.84M | -$1.96M |
| Total Equity | $2.93M | $4.33M | -$2.84M | -$1.96M |
Cash Flow Statement (Annual) · Reported in USD · Newest filing period first.
Cash Flow Statement (Quarterly) · Reported in USD · Newest filing period first.
| Cash Flow Statement | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|---|
| Net Income | -$1.47M | -$3.77M | -$923K | -$1.91M | -$656K | -$540K |
| Depreciation & Amortization | $1.2K | $1.2K | $1.2K | $1.2K | $1.2K | $1.2K |
| Stock-Based Compensation | $69K | $61K | $46K | $1.20M | $49K | $54K |
| Change in Payables | $74K | -$382K | $167K | $199K | -$131K | $44K |
| Operating Cash Flow | -$1.26M | -$2.10M | -$350K | -$610K | -$509K | -$404K |
| Financing Cash Flow | $0 | $6.68M | $125K | $0 | $1.30M | $200K |
| Net Change in Cash | $239K | $2.57M | -$225K | -$610K | $791K | -$204K |
Margins, returns, leverage, liquidity, and year-over-year growth computed directly from SEC EDGAR statement levels. Multi-year figures show cumulative per-share growth.
Quarterly margins, ROE, and ROA use trailing-twelve-month (TTM) flows summed across four contiguous quarters. Growth rates are true year-over-year comparisons against the same quarter a year earlier.
| Ratios & Growth | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|---|
| Current Ratio | 5.22x | 7.70x | 0.02x | -- | -- | -- |
| Quick Ratio | 4.94x | 7.29x | 0.00x | -- | -- | -- |
| Debt to Equity | 0.02x | 0.02x | -- | -- | -- | -- |